Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)

Open Posted

Opportunity number
RFA-NS-28-012
Agency
Applications due
Award size
Up to $2,500,000

Opportunity facts

Funding instrument
Cooperative Agreement
Category
  • Health
Eligible applicants
  • Special District Governments
  • County Governments
  • Tribal Governments (Federally Recognized)
  • Higher Education Inst. (Private)
  • For Profit Organizations
  • Independent School Districts
  • Other
  • State Governments
  • City/Township Governments
  • Tribal Organizations (Not Federally Recognized)
  • 501(c)(3) Nonprofits
  • Small Businesses
  • Public or Indian Housing Auth.
  • Non-501(c)(3) Nonprofits
  • Higher Education Inst. (Public)
Points of contact

Opportunity details come from Grants.gov. Updated .

About this opportunity

The National Institutes of Health, through NINDS and co-administered with the National Institute on Aging, is forecasting a cooperative agreement program (RFA-NS-28-012, U01) to fund translational development of genomic and biologic therapeutic candidates for Alzheimer's Disease-Related Dementias, with first-cycle applications due October 6, 2027. The February 12, 2026 forecast states applications are not being solicited at this time, and the full announcement posted November 3, 2026 supersedes it with the dates below. The full announcement limits eligibility to U.S. organizations, including educational institutions, nonprofits, for-profit companies, government agencies, and tribal organizations, and states that non-domestic entities and foreign components are not eligible. The forecast's broader applicant list, which included foreign institutions, is superseded by this restriction.

NINDS intends to commit $6 million in each of FY2028 and FY2029 to fund up to 3 awards annually, contingent upon appropriations and meritorious applications. Individual applications may request up to $1.3 million in direct costs annually, or up to $2.5 million if including Phase 1 first-in-human clinical trials, with a maximum project period of 5 years.

The program supports milestone-driven projects spanning therapeutic optimization through IND-enabling studies and early clinical evaluation, including genome editing construct optimization, pharmacokinetic/pharmacodynamic assessment, biodistribution studies, manufacturing scale-up, formulation development, regulatory strategy, and preparatory clinical studies. Eligible indications are Frontotemporal Dementia, Lewy Body Dementias, Vascular Contributions to Cognitive Impairment and Dementia, and Multiple Etiology Dementias. Applications proposing basic disease mechanism research, new animal model development, target identification without defined therapeutic candidates, stand-alone diagnostic development, or clinical trials primarily designed to demonstrate efficacy will not be reviewed.

Dates: earliest submission January 9, 2027; applications due October 6, 2027 (first cycle) and October 10, 2028 (second and third cycles); scientific merit review July 2027; advisory council review October 2027; earliest start December 2027. Applications are evaluated on scientific merit, rigor and feasibility, investigator expertise, and alignment with translational development milestones, with no weighting specified. Substantial ongoing NIH programmatic involvement includes participation in regulatory meetings and milestone monitoring. Applicants must complete SAM registration, obtain a Unique Entity Identifier, register with eRA Commons and Grants.gov, and obtain ORCID profiles for all PD/PIs before submission.

The opportunity is assigned to Assistance Listing 93.853 (Extramural Research Programs in the Neurosciences and Neurological Disorders), 93.866 (Aging Research), and 93.NS1 (Neurosciences and Neurological Disorders – Research Projects). No incumbent recipient is named.

Synopsis

This Notice of Funding Opportunity (NOFO) supports the translation of genome editing and other biologic therapies for Alzheimer's Disease-Related Dementias (ADRD). The program spans the full translational pipeline, from therapeutic lead optimization and drug product development through IND-enabling studies and early clinical evaluation. Supported activities may include optimization of editing constructs and delivery systems; assessment of bioactivity, target engagement, durability, pharmacokinetics, and bioavailability; demonstration of in vivo efficacy; execution of safety pharmacology and toxicology studies; and development of scalable manufacturing processes, formulation strategies, and quality attributes aligned with regulatory expectations.

ADRD include Frontotemporal Dementia (FTD); Lewy Body Dementias (LBD), including Dementia with Lewy Bodies (DLB) and Parkinson's Disease Dementia (PDD); Vascular Contributions to Cognitive Impairment and Dementia (VCID); and Multiple Etiology Dementias (MED).

Eligibility

Other Eligible ApplicantsEligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

Files

File Type Posted
PKG00294512.pdf PDF
RFA-NS-28-012-Full-Announcement.html HTML file

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar grant opportunities
  • Ask GovTribe AI about this opportunity